Skip to main content
. 2023 Jul 28;13:12236. doi: 10.1038/s41598-023-39236-w

Figure 8.

Figure 8

Drug candidates with chiral methylenepyridine and hydroxypyridine moietis. (A) Cell viability (MTT assay) evaluated following glioblastoma cell (LN229) exposure to 25 μM of the corresponding BPA-pyrimidines. Data indicate average values with standard deviation (n = 3). (B) Tabulated values for glioblastoma-relevant parameters. CV = Cell viability (% of control) mean ± SD at 25 μM; ClogD = calculated distribution coefficient at physiological pH (lipophilicity); MPA = Minimal Projection Area (Å2); PL = Molecular Polarizability (Å3); ELUMO = energy of LUMO (Lowest Unoccupied Molecular Orbital) (eV); EHOMO = Energy of HOMO (Highest Occupied Molecular Orbital) (eV). (C) IC50 graphs and pictures of the cells at 5 and 25 µM for HR87 and HR90. Data represent average values with standard deviation (n = 3).